Ignite Creation Date:
2024-05-06 @ 3:22 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02274610
Status:
COMPLETED
Last Update Posted:
2017-05-01
First Post:
2014-10-14
Brief Title:
Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer
Sponsor:
Samyang Biopharmaceuticals Corporation
Organization:
Samyang Biopharmaceuticals Corporation
Study Overview
Official Title:
Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOPNP201
Brief Summary:
Evaluation of the pharmacokinetic equivalence of two Docetaxel formulations in terms of AUC and Cmax
Detailed Description:
Comparison of pharmacokinetic parameters T12β CL Vdss Safety as measured by adverse events
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None